HEALTHWAREHOUSE.COM - HEWA STOCK NEWS

HealthWarehouse.com, Inc. (HEWA) reported a 3% decrease in net sales totaling $5.1 million for the first quarter of 2024 compared to the same period in 2023. The company reported a net loss of $252,412 and positive EBITDA of $89,723 for the quarter. Despite the decline in revenue, HealthWarehouse.com experienced a 7% growth in direct-to-consumer prescription sales. The company remains optimistic about future sales growth in 2024, focusing on new partnerships and recovering lost sales due to supply issues. HealthWarehouse.com continues to invest in technology to enhance operational efficiency and customer experience. Gross profit decreased by 10.0% due to lower sales and margins. Operating expenses decreased by 8.8% primarily in advertising, marketing, shipping, and salaries, offset by increased expenses in software engineering and stock-based compensation. The company reported a net loss of $252,000 for the quarter, an improvement from the previous year, and an Adjusted EBITDA of $90,000.

HealthWarehouse.com, Inc. (HEWA) reports a 12% increase in revenues, reaching $20.3 million for the year ended December 31, 2023. The company experienced positive cash flow following the launch of new software, with a significant improvement in the second half of the year. Despite a net loss of $1.8 million, HealthWarehouse.com focuses on enhancing operational efficiency and customer experience for future growth.

HEWA: HealthWarehouse.com Reports 10% Increase in Prescription Revenues, Positive Cash Flow. Net sales for Q3 2023 were $4.8M, a 2% increase YoY. Prescription revenues increased by 10%, but a net loss of $299,000 was reported. The company remains focused on increasing access to healthcare products and investing in proprietary technology.

HealthWarehouse.com, Inc. reports a 27% increase in revenues for the second quarter of 2023, reaching $5.3 million. The company also announced its inclusion in Forbes' list of best online pharmacies. However, HealthWarehouse.com experienced a net loss of $477,000 for the quarter and $825,000 for the six months ended June 30, 2023.

HealthWarehouse.com, Inc. (OTCQB:HEWA) reported a 12% increase in net sales for 2022, totaling $18,142,633 driven by significant growth in partner services revenue. However, the company experienced a net loss of $952,029, worsening from $572,502 in 2021. Despite this, HealthWarehouse.com achieved positive cash flow for the sixth consecutive year with an Adjusted EBITDA of $146,787. Direct-to-consumer sales declined by 3.5%, while partner services revenue nearly doubled. Operating expenses rose by 10.7% to $12,725,433, largely due to increased shipping and salaries. The company plans to launch a new e-commerce platform in 2023.

HealthWarehouse.com, Inc. (OTC:HEWA) reported net sales of $4,681,302 for Q3 2022, an 11% increase from Q3 2021, driven by growth in partner services. The company recorded a loss from operations of $225,614, yet reported positive cash flow with an Adjusted EBITDA of $47,673. Prescription sales increased by 6.4% to $3,873,323, and OTC sales surged 46.2% to $736,265. Despite higher gross profit, operating expenses rose by 11.2%, leading to net losses slightly widening compared to last year. Future plans include launching a proprietary e-commerce platform aimed at improving customer retention.

HealthWarehouse.com, Inc. (OTC:HEWA) reported a 6% revenue increase in Q2 2022, totaling $4,199,832, driven by growth in partner services. However, the company experienced operational losses of $293,524 for the quarter and $507,512 for the first half of the year. Prescription sales rose by 4.5%, while over-the-counter sales jumped by 18.1%. Despite the revenue growth, gross margins declined slightly, and operating expenses increased by nearly 10%. The company is planning to launch a new e-commerce platform in Q4 2022 and has been recognized as a Top Workplace in Greater Cincinnati.

HealthWarehouse.com (OTC:HEWA) reported a 13% increase in revenues, totaling $4,314,980 for Q1 2022, driven by strong partner services and direct-to-consumer sales. Despite a reported operating loss of $213,988, the company achieved positive cash flow of $64,047 as per Adjusted EBITDA. Gross profit increased by $198,460 (7.5%), albeit with a declining gross margin of 66.1%. Operating expenses rose by 10.3% to $3,022,021, influenced by increased salaries and marketing costs. The company was recognized by Consumer Reports for its full range of prescription offerings.